A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01796171 |
Recruitment Status :
Recruiting
First Posted : February 21, 2013
Last Update Posted : May 13, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-Hodgkin Lymphoma Follicular Lymphoma | Drug: Betalutin | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 204 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I/II Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma. |
Actual Study Start Date : | December 2012 |
Estimated Primary Completion Date : | December 2020 |
Estimated Study Completion Date : | September 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Part A, Arm 1: with lilotomab pre-dosing
Betalutin, 10 MBq/kg b.w. in escalated doses with lilotomab pre-dosing.
|
Drug: Betalutin
Betalutin, 10 MBq/kg b.w. in escalated doses with 40 mg lilotomab pre-dosing |
Experimental: Part A, Arm 2: without pre-dosing
Betalutin, 15 MBq/kg b.w. in escalated doses without pre-dosing.
|
Drug: Betalutin
Betalutin, 15 MBq/kg b.w. in escalated doses without pre-dosing |
Experimental: Part A, Arm 3: with rituximab pre-dosing
Betalutin, 15 MBq/kg b.w. in escalated doses with rituximab pre-dosing.
|
Drug: Betalutin
Betalutin, 15 MBq/kg b.w. in escalated doses with rituximab pre-dosing |
Experimental: Part A, Arm 4: with higher dose lilotomab pre-dosing
Betalutin, 15 MBq/kg b.w. in escalated doses with a higher dose lilotomab pre-dosing regimen.
|
Drug: Betalutin
Betalutin, 15 MBq/kg b.w. in escalated doses with 100 mg/m2 lilotomab pre-dosing |
Experimental: Part A, Arm 5: with intermediate dose lilotomab pre-dosing
Betalutin, 20 MBq/kg b.w. with an intermediate dose lilotomab pre-dosing regimen.
|
Drug: Betalutin
Betalutin, 20 MBq/kg b.w. in escalated doses with 60 mg/m2 lilotomab pre-dosing |
Experimental: Part B
Betalutin, 15 MBq/kg b.w. with 40mg lilotomab compared to Betalutin, 20 MBq/kg b.w. with 100mg/m2 lilotomab
|
Drug: Betalutin
Betalutin, 15 MBq/kg b.w. with 40mg lilotomab compared to Betalutin, 20 MBq/kg b.w. with 100 mg/m2 lilotomab |
- Part A, Phase I [ Time Frame: 12 weeks ]To define Maximum tolerated dose (MTD) of Betalutin Adverse events and abnormal laboratory values will be graded for toxicity according to CTCAE version 4.
- Part A, Phase IIa [ Time Frame: 3 months - 5 years ]To explore tumour response rates in patients receiving Betalutin
- Part B, Phase IIb [ Time Frame: 3 months - 5 years ]Overall response rate

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Part A:
Inclusion Criteria:
- Histologically confirmed (by WHO classification) relapsed incurable non-Hodgkin B-cell lymphoma of following subtypes; follicular grade I-IIIA, marginal zone, small lymphocytic, lymphoplasmacytic, mantle cell.
- Age ≥ 18 years
- A pre-study WHO performance status of 0-1
- Life expectancy should be ≥ 3 months
- <25% tumour cells in bone marrow biopsy
- Measurable disease by radiological methods
Exclusion Criteria:
- Absolute Neutrophil Counts (ANC) ≤ 1.5 x 109 /l
- Platelet count ≤ 150 x 109 /l
- Total bilirubin ≥ 30 mmol/l
- ALP and ALAT ≥ 4x normal level
- Creatinine ≥ 115 µmol/l (men), 97 µmol/l (women))
- Known CNS involvement of lymphoma
- Previous total body irradiation
- Known history of HAMA
- Chemotherapy or immunotherapy received within the last 4 weeks prior to start of study treatment. Pretreatment with rituximab is allowed
- Previous hematopoietic stem cell transplantation (autologous and allogenic)
- Previous treatment with radioimmunotherapy
- Receipt of live, attenuated vaccine within 30 days prior to enrolment
- Test positive for hepatitis B (HBsAg and anti-HBc)
- A known hypersensitivity to rituximab, HH1, Betalutin or murine proteins or any excipient used in rituximab, HH1 or Betalutin
Part B:
Inclusion Criteria:
- Histologically confirmed (by WHO classification) relapsed non-Hodgkin B-cell FL (follicular grade I-IIIA).
- Male or female aged ≥ 18 years.
- Received at least 2 prior chemotherapy- or immunotherapy-based regimens. Prior therapy must include a rituximab/anti-CD20 agent and alkylating agent. Prior exposure to other systemic anti-neoplastic agents (including idelalisib or other PI3K inhibitors) is also allowed.
- Patients must be refractory to any previous regimen containing rituximab/anti-CD20 agent, defined as no response (no CR or PR) during therapy or a response (CR/PR) lasting less than 6 months after the completion of a regimen of rituximab/anti-CD20 therapy (including occurrence of progressive disease (PD) during rituximab/anti-CD20 maintenance therapy, or within 6 months of completion of maintenance therapy).
- WHO performance status of 0-2.
- Life expectancy of ≥ 3 months.
- Bone marrow tumour infiltration < 25% (in biopsy taken from a site not previously irradiated).
- Measurable disease by CT or MRI: longest diameter (LDi) > 1.5 cm for nodal lesion, LDi > cm for extra nodal lesion within 28 days prior to start of treatment.
- ANC ≥ 1.5 x 109/L.
- Platelet count ≥ 150 x 109/L.
- Haemoglobin ≥ 9.0 g/dL.
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except patients with documented Gilbert's syndrome [< 3.0 mg/dL]).
- Liver enzymes: Aspartate transaminase (AST); Alanine transaminase (ALT) or ALP ≤ 2.5 x ULN (or ≤ 5.0 x ULN with liver involvement by primary disease).
- Adequate renal function as demonstrated by a serum creatinine < 1.5 x ULN.
- Negative HAMA test at screening.
- Negative test at screening for Hepatitis B (negative HBsAG and anti-HBC), Hepatitis C and HIV.
Exclusion Criteria:
- Prior hematopoietic allogenic stem cell transplantation.
- Prior autologous stem cell transplantation.
- Evidence of histological transformation from FL to DLBCL at time of screening.
- Previous total body irradiation.
- Prior anti-lymphoma therapy (chemotherapy, immunotherapy or other investigational agent) within 4 weeks prior to start of study treatment (corticosteroid treatment at doses of ≤ 20 mg/day, topical or inhaled corticosteroids, G-CSF or GM-CSF are permitted up to 2 weeks prior to start of study treatment). Note: excludes pre-treatment with rituximab as part of this study.
- Patients with known or suspected CNS involvement of lymphoma.
- History of a previous treated cancer except for the following: adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, localised prostate cancer undergoing surveillance or surgery, localised breast cancer treated with surgery and radiotherapy but not including systemic chemotherapy, other adequately treated Stage 1 or 2 cancer currently in CR.
- Exposure to another CD37 targeting drug.
- A known hypersensitivity to rituximab, lilotomab, Betalutin or murine proteins or any excipient used in rituximab, lilotomab, or Betalutin.
- Has received a live-attenuated vaccine within 30 days prior to enrolment.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01796171
Contact: Clinical Trials | clinicaltrials@nordicnanovector.com |

Principal Investigator: | Arne Kolstad, MD, PhD | Oslo University Hospital |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Nordic Nanovector |
ClinicalTrials.gov Identifier: | NCT01796171 |
Other Study ID Numbers: |
EudraCT: 2011-000033-36 |
First Posted: | February 21, 2013 Key Record Dates |
Last Update Posted: | May 13, 2020 |
Last Verified: | May 2020 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Radioimmunotherapy Lu-177 Phase I study Phase II study Betalutin |
Lymphoma Lymphoma, Non-Hodgkin Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |